Article PDF
Avoid common mistakes on your manuscript.
Literatur
Bundesärztekammer (2009) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzteverlag, Köln
Bundesärztekammer (2017) Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie). Ärzteverlag, Köln
Price TH, Boeckh M, Harrison RW et al (2015) Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 126:2153–2161
Schrezenmeier H, Körper S, Höchsmann B, Weinstock C (2019) Transfusion Support. In: Carreras E, Dufour C, Mohty M, Kröger N (eds) The EBMT Handbook Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer Open:163–170. https://doi.org/10.1007/978-3-030-02278-5
Ambruso DR (2015) Hydroxyethyl starch and granulocyte transfusions: considerations of utility and toxicity profile for patients and donors. Transfusion 55:911–918
Bux J, Cassens U, Dielschneider T et al (2003) Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 85:322–325
Ikemoto J, Yoshihara S, Fujioka T et al (2012) Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy. Transfusion 52:2646–2652
Quillen K, Yau YY, Leitman SF (2009) The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. Transfusion 49:421–426
Lee JH, Leitman SF, Klein HG (1995) A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. Blood 86:4662–4666
Price TH, Bowden RA, Boeckh M et al (2000) Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302–3309
Dullinger K, Pamler I, Brosig A et al (2017) Granulocytapheresis with modified fluid gelatin versus high-molecular-weight hydroxyethyl starch: a matched-pair analysis. Transfusion 57:397–403
Doblinger N, Bredthauer A, Mohrez M et al (2019) Impact of hydroxyethyl starch and modified fluid gelatin on granulocyte phenotype and function. Transfusion 59:2121–2130
Mastronardi R, Cleophax S, Begue S et al (2019) Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis. Transfus Clin Biol 26:164–170
Sahlin A, Blomgran R, Berlin G (2019) Granulocyte concentrates prepared from residual leukocyte units produced by the Reveos automated blood processing system. Transfus Apher Sci. https://doi.org/10.1016/j.transci.2019.102682:102682
Van De Geer Gazendam Tool ARPAT et al (2017) Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products. Vox Sang 112:173–182
Guidet B, Martinet O, Boulain T et al (2012) Assessment of hemodynamic efficacy and safety of 6 % hydroxyethylstarch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94
Myburgh JA, Finfer S, Bellomo R et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911
Perner A, Haase N, Guttormsen AB et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134
Annane D, Fuchs-Buder T, Zoellner C, Kaukonen M, Scheeren TWL (2018) EMA recommendation to suspend HES is hazardous. Lancet 391:736–738
Qureshi SH, Rizvi SI, Patel NN, Murphy GJ (2016) Meta-analysis of colloids versus crystalloids in critically ill, trauma and surgical patients. Br J Surg 103:14–26
Taylor C, Thompson K, Finfer S et al (2016) Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. Lancet Respir Med 4:818–825
BfArM (2018) Rote-Hand-Brief zu Hydroxyethylstärke (HES)-haltigen Arzneimitteln zur Infusion. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hes.html. Zugegriffen: 18. März 2020
BfArM (2018) Bescheid vom 31.07.2018. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/RisikoBewVerf/g-l/hes-stufenplanbescheid.pdf?__blob=publicationFile&v=2. Zugegriffen: 18. März 2020
BfArM (2019) Hydroxyethylstärke (HES): Risiko von Nierenschädigungen und tödlichen Verläufen – Informationen für Angehörige der Heilberufe 15.04.2019. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/RisikoBewVerf/g-l/hes_blaue-hand-brief.pdf;jsessionid=CF66B17A403999ABA64A43FAB2955AF5.1_cid354?__blob=publicationFile&v=2. Zugegriffen: 18. März 2020
Axdorph Nygell U, Sollen-Nilsson A, Lundahl J (2015) Eighteen years experience of granulocyte donations-acceptable donor safety? J Clin Apher 30:265–272
Pagano MB, Harmon C, Cooling L et al (2016) Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity. Transfusion 56:2848–2856
European Society of Anaesthesiology ESA Academy. https://academy.esahq.org/volumetherapy. Zugegriffen: 18. März 2020
DGTI (2019) Empfehlungen der DGTI zum Einsatz von Hydroxyethylstärke als Sedimentationsbeschleuniger bei der Granulozytapherese. Transfus Med Hemother 46:304–307
Rights and permissions
About this article
Cite this article
Einsatz von Hydroxyethylstärke (HES) als Sedimentationsbeschleuniger bei der Gewinnung von Granulozytenkonzentraten. Bundesgesundheitsbl 63, 792–795 (2020). https://doi.org/10.1007/s00103-020-03141-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00103-020-03141-8